홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

이옥실란(400MG)

Ioxilan

HCID 3743
새 반응
인쇄

데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다

기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
107793-72-6
표준 SMILES
CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCCO)c(I)c(C(=O)NCC(O)CO)c1I
InChIKey
UUMLTINZBQPNGF-UHFFFAOYSA-N
분자식
C18H24I3N3O8
평균 분자량
791.1 g/mol
단동위원소 질량
790.8698

개요

Ioxilan is an amidobenzoic acid.

이름 및 식별자

우선 이름
Ioxilan
IUPAC
5-[acetyl(2,3-dihydroxypropyl)amino]-3-N-(2,3-dihydroxypropyl)-1-N-(2-hydroxyethyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
현지명
이옥실란(400MG)
영어명
IOXILAN (400 MG)
분자식
C18H24I3N3O8
분자량
791.11

이름 및 동의어

ioxilan107793-72-6OxilanIoxitolIoxilaneIoxilanumOxilan-300Oxilan-350LoxilanDTXSID0048717A4YJ7J11TGNSC-760056
이름 더 보기
이옥실란(400MG)Oxilan 300IOXILAN (400 MG)Ioxilan (1345206)5-[Acetyl(2,3-dihydroxypropyl)aMino]-N1-(2,3-dihydroxypropyl)-N3-(2-hydroxyethyl)-2,4,6-triiodo-1,3-benzenedicarboxaMide1,3-Benzenedicarboxamide, 5-[acetyl(2,3-dihydroxypropyl)amino]-N-(2,3-dihydroxypropyl)-N'-(2-hydroxyethyl)-2,4,6-triiodo-1,3-Benzenedicarboxamide, 5-[acetyl(2,3-dihydroxypropyl)amino]-N1-(2,3-dihydroxypropyl)-N3-(2-hydroxyethyl)-2,4,6-triiodo-5-[acetyl(2,3-dihydroxypropyl)amino]-3-N-(2,3-dihydroxypropyl)-1-N-(2-hydroxyethyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
N-(2,3-Dihydroxypropyl)-5-(N-(2,3-dihydroxypropyl)acetamido)-N'-(2-hydroxyethyl)-2,4,6-triiodoisophthalamideDTXCID70286431,3-Benzenedicarboxamide, 5-(acetyl(2,3-dihydroxypropyl)amino)-N-(2,3-dihydroxypropyl)-N'-(2-hydroxyethyl)-2,4,6-triiodo-N1-(2,3-dihydroxypropyl)-5-[N-(2,3-dihydroxypropyl)acetamido]-N3-(2-hydroxyethyl)-2,4,6-triiodobenzene-1,3-dicarboxamideN1-(2,3-dihydroxypropyl)-5-(N-(2,3-dihydroxypropyl)acetamido)-N3-(2-hydroxyethyl)-2,4,6-triiodobenzene-1,3-dicarboxamideRefChem:57668V08AB125-(N-2,3-dihydroxypropylacetamido)-2,4,6-triiodo-N-(2-hydroxyethyl)-N'-(2,3-dihydroxypropyl)isophthalamide

물성

구조 계산 물성보충 중

XLogP
-2.4
극성 표면적
180 Ų
수소 결합 공여자 수
7
수소 결합 수용자 수
8
회전 가능 결합 수
11
무거운 원자 수
32
형식 전하
0
복잡도
647

실험 및 물리화학적 성질

Human Drugs · 3건

Breast Feeding; Lactation; Milk, Human; Contrast Media; Diagnostic Agents

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

물리화학적 성질

끓는 점
827.8 · 827.8±65.0 °C(Predicted)
밀도
2.205 · 2.205±0.06 g/cm3(Predicted)
저장 조건
-20 °C · Store at -20°C
용해도
250 mg/mL · DMSO: ≥ 250 mg/mL (316.01 mM)
산도 계수 (pKa)
11.47 · 11.47±0.46(Predicted)
물리적 상태
Solid
색상
White to off-white
주요 응용
의약품(소분자)
InChI
1S/C18H24I3N3O8/c1-8(28)24(5-10(30)7-27)16-14(20)11(17(31)22-2-3-25)13(19)12(15(16)21)18(32)23-4-9(29)6-26/h9-10,25-27,29-30H,2-7H2,1H3,(H,22,31)(H,23,32)
InChIKey
UUMLTINZBQPNGF-UHFFFAOYSA-N
SMILES
Ic1c(c(c(c(c1C(=O)NCC(O)CO)I)C(=O)NCCO)I)N(CC(O)CO)C(=O)C
EPA
1 · 1,3-Benzenedicarboxamide, 5-[acetyl(2,3-dihydroxypropyl)amino]-N1-(2,3-dihydroxypropyl)-N3-(2-hydroxyethyl)-2,4,6-triiodo- (107793-72-6)

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

독성 정보

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

안전 데이터

wgk
WGK 3
HS 번호
2924296000
스토리지 클래스
11 - Combustible Solids

화학 및 산업

약리 정보

ATC Code · 2건

V - Various

QV - Various

Protein BindingBinding of ioxilan to plasma protein is negligible.
PharmacodynamicsAs with other iodinated contrast agents the degree of contrast enhancement is directly related to the iodine content in the administered dose.
Mechanism of ActionIntravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs.
Biological Half-LifeAn initial fast distribution phase with a half-life of 13.1 ± 4.2 minutes (women) or 23.5 ± 15.3 minutes (men) was followed by an elimination phase with a half-life of 102.0 ± 16.9 minutes (women) and 137 ± 35.4 minutes (men).
Metabolism/MetabolitesThere is no evidence for metabolism.
FDA Pharmacological Classification · 5건

A4YJ7J11TG

IOXILAN

Established Pharmacologic Class [EPC] - Radiographic Contrast Agent

Mechanisms of Action [MoA] - X-Ray Contrast Activity

Ioxilan is a Radiographic Contrast Agent. The mechanism of action of ioxilan is as a X-Ray Contrast Activity.

MeSH Pharmacological ClassificationSubstances used to allow enhanced visualization of tissues.
Absorption, Distribution and Excretion · 4건

Peak iodine plasma levels occur immediately following rapid intravenous injection. Iodine plasma levels fall rapidly within 5 to 10 minutes. This can be accounted for by the dilution in the vascular and extravascular fluid compartments.

The average amount of ioxilan excreted unchanged in urine at 24 hours represents 93.7% of the dose in young healthy subjects (21-27 years) after intravenous administration. This finding suggests that, compared to the renal excretion, biliary and/or gastrointestinal excretion are not important.

관련 반응

0건
반응 기록 만들기
아직 관련 반응이 없습니다

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트

데이터베이스 식별자

CAS
107793-72-6
PubChem CID
3743
DTXSID
DTXSID0048717
ChEMBL
CHEMBL1201075
ChEBI
CHEBI:135884
UNII
A4YJ7J11TG
Nikkaji
J518.532G

Ioxilan is distributed mainly in the blood as suggested by the apparent volume of distribution (central compartment), 7.2 ± 1.0 L in women and 10.0 ± 2.4 L in men

The total clearance values were 95.4 ± 11.1 mL·min-1 and 101.0 ± 14.7 mL·min-1 and the renal clearance values were 89.4 ± 13.3 mL·min-1 and 94.9 ± 16.6 mL·min-1 for women and men, respectively.

응용 분야

용도Nonionic iodinated contrast medium. Diagnostic aid (radiopaque medium).